Cargando…
Indoleamine 2,3-Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma
INTRODUCTION: Tumour-emitted molecules induce immunosuppression in the tumour microenvironment. An immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO/IDO1), facilitates immune escape in several malignant tumours, including osteosarcoma. Upregulation of IDO establishes a tolerogenic environme...
Autores principales: | Farooq, Asim, Zulfiqar, Bilal, Asghar, Kashif |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore. Pakistan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187603/ https://www.ncbi.nlm.nih.gov/pubmed/37197000 http://dx.doi.org/10.37029/jcas.v9i1.501 |
Ejemplares similares
-
Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma
por: Asghar, Kashif, et al.
Publicado: (2017) -
Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase
por: Asghar, Kashif, et al.
Publicado: (2021) -
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
por: Zulfiqar, Bilal, et al.
Publicado: (2017) -
Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis
por: ASGHAR, KASHIF, et al.
Publicado: (2015) -
The immunotherapeutic role of indoleamine 2,3‐dioxygenase in head and neck squamous cell carcinoma: A systematic review
por: Lin, Daniel J., et al.
Publicado: (2021)